Below are the general guidelines for dosing finasteride. Note that these dosages may be adjusted on a case-by-case basis for individual patients by a provider. Always follow your prescribing physician’s instructions for taking finasteride.
The following information comes from DailyMed, the official FDA label information provider for drugs.
What if I miss a dose of Finasteride?
If you miss a dose of this medicine, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
What if I overdose on Finasteride?
Patients have received single doses of finasteride up to 400 mg and multiple doses of PROSCAR up to 80 mg/day for three months without adverse effects. Until further experience is obtained, no specific treatment for an overdose with finasteride can be recommended.
Significant lethality was observed in male and female mice at single oral doses of 1500 mg/m2 (500 mg/kg) and in female and male rats at single oral doses of 2360 mg/m2 (400 mg/kg) and 5900 mg/m2 (1000 mg/kg), respectively.
How is Finasteride administered?
Finasteride may be administered with or without meals.
The recommended dose of finasteride for benign prostatic hyperplasia (BPH) is one tablet (5 mg) taken once a day.
For androgenetic alopecia (male hair loss) the dose is 1 mg once a day.
Combination with Alpha-Blocker
The recommended dose of finasteride one tablet (5 mg) taken once a day in combination with the alpha-blocker doxazosin.
How is Finasteride supplied?
No. 3094 — finasteride tablets 5 mg are blue, modified apple-shaped, film-coated tablets, with the code MSD 72 on one side and finasteride on the other. They are supplied as follows:
NDC 0006-0072-31 unit of use bottles of 30
NDC 0006-0072-58 unit of use bottles of 100.
Storage and Handling
Store at room temperatures below 30°C (86°F). Protect from light and keep the container tightly closed.
Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus.